RATIONALE: Diagnostic procedures, such as MRI, may help measure oxygen levels in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying how well MRI works in assessing hypoxia in patients with localized prostate cancer undergoing stereotactic body radiation therapy.
No linked publications found in PubMed
DISEASE CHARACTERISTICS: * Biopsy proven adenocarcinoma of the prostate * Localized disease * Scheduled to undergo treatment with stereotactic body radiotherapy (SBRT) on a phase II clinical trial * Has not yet started SBRT PATIENT CHARACTERISTICS: * Serum creatinine ≤ 1.2 mg/dL * No claustrophobia * No other contraindication to MRI (e.g., implanted pacemaker device) * No known allergy to MRI contrast PRIOR CONCURRENT THERAPY: * No prior treatment for prostate cancer (e.g., hormonal therapy or chemotherapy)